Antiplatelet and Antithrombotic Therapy After Patent Foramen Oval and Atrial Septal Defect Closure

Area of Science:

• Cardiology
• Interventional Cardiology
• Cardiovascular Medicine

Background:

• Atrial septal pathologies range from patent foramen ovale (PFO) to various types of atrial septal defects (ASDs), including secundum, primum, and sinus venosus defects.
• Percutaneous closure of interatrial shunts has become a standard, safe, and effective treatment option over recent decades.
• Successful percutaneous closure necessitates careful management of the balance between thrombotic risk, device function, and bleeding complications.

Purpose of the Study:

• To review current data on antiplatelet and antithrombotic management strategies.
• To provide guidance for patients who have undergone percutaneous closure of ASDs or PFOs.
• To address the critical balance between preventing thrombosis and minimizing bleeding risk post-procedure.

Main Methods:

• Systematic review of existing literature and clinical data.
• Analysis of antiplatelet and antithrombotic therapies used in patients post-percutaneous closure.
• Evaluation of the efficacy and safety profiles of different management strategies.

Main Results:

• The review synthesizes current evidence regarding pharmacological management following device closure.
• It highlights the importance of individualized patient assessment for tailoring antithrombotic therapy.
• Data on optimal duration and type of antiplatelet/antithrombotic agents are discussed in relation to procedural outcomes.

Conclusions:

• Appropriate antiplatelet and antithrombotic therapy is essential for optimizing outcomes after percutaneous closure of ASDs and PFOs.
• Further research may be needed to establish definitive guidelines for long-term management.
• The findings underscore the need for a nuanced approach to anticoagulation and antiplatelet therapy in this patient population.